查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2129337

2034年獸用幹細胞療法市場預測－依療法、細胞來源、動物種類、應用、最終使用者和地區分類的全球分析

Veterinary Stem Cell Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type (Autologous Stem Cell Therapy and Allogeneic Stem Cell Therapy), Cell Source, Animal Type, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球獸醫幹細胞治療市場規模將達到 1.724 億美元，並在預測期內以 9.6% 的複合年成長率成長，到 2034 年將達到 3.591 億美元。

獸用幹細胞療法是再生醫學領域的一個快速發展分支，它利用幹細胞修復動物受損組織、抑制發炎並治療慢性疾病。這些療法主要用於治療骨關節炎、整形外科疾病、肌腱和韌帶損傷以及其他影響伴侶動物和運動動物的退化性疾病。此領域涵蓋多種細胞來源，如脂肪來源幹細胞、骨髓來源幹細胞、臍帶血來源幹細胞和周邊血液來源幹細胞，其應用範圍廣泛，涵蓋多種動物物種。

寵物日益“人性化”，以及對先進獸醫護理的需求不斷成長。

寵物飼主與愛寵之間日益加深的情感紐帶是推動獸醫幹細胞療法市場發展的主要動力。寵物越來越被視為家庭成員，因此，飼主更願意投資於先進、高品質的醫療手段，以延長寵物的壽命並提高其生活品質。這一趨勢反映在全球寵物相關支出的成長上，預計2025年，美國寵物相關支出將達到1,570億美元。人們對能夠解決慢性疾病（例如骨關節炎）緩解疾病療法」的需求不斷成長，推動了幹細胞再生療法的應用。隨著寵物飼主為年長的寵物尋求創新且長效的解決方案，對幹細胞療法的需求持續成長。

高昂的醫療成本和缺乏監管透明度

儘管獸用幹細胞療法市場具有巨大的成長潛力，但仍面臨許多限制因素，主要包括治療費用高昂和監管政策不明朗。幹細胞療法涉及細胞採集、處理和給藥等複雜流程，價格昂貴，因此並非所有寵物飼主都能負擔得起。獸用幹細胞產品缺乏統一的全球監管標準，造成了不確定性，可能延緩新療法的批准和商業化，尤其是在嚴格監管的地區。此類監管不一致可能會限制可用療法的數量，並加重生產商的負擔，從而阻礙市場成長。

幹細胞產品的法規核准和標準化

標準化幹細胞產品有望獲得監管部門批准，這將為市場擴張帶來巨大機會。例如，Gallant公司用於治療貓科動物疼痛疾病的幹細胞療法預計將獲得美國FDA的有條件批准，這將是一個里程碑式的事件，有助於增強獸醫和寵物飼主的信心。這將證明這些療法的安全性和有效性，促進其在臨床實踐中的更廣泛應用，並吸引更多投資進入該領域。可規模化、易於取得的異體療法的開發有望提高再生醫學的分配效率和可及性，填補慢性疾病治療領域的關鍵空白。

與替代療法的競爭以及缺乏證據

獸醫幹細胞療法市場面臨其他療法的威脅，以及關於其證據深度的持續爭論。儘管幹細胞療法前景廣闊，但它仍需與其他先進療法（例如富血小板血漿 (PRP) 和傳統藥物）競爭，以治療類似的疾病。不同應用和動物物種中支持幹細胞療效的臨床證據存在差異，這可能導致一些獸醫對其持懷疑態度。加之幹細胞療法的高昂成本，有些獸醫可能更傾向於選擇成熟、成本較低且擁有更可靠長期數據的替代療法。克服這種認知偏差並建立更強大的證據基礎對於市場成長至關重要。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對獸醫幹細胞治療市場的影響喜憂參半。初期，非緊急手術的動物醫院服務受限，細胞處理供應鏈中斷，這些都是主要影響因素。然而，疫情封鎖期間人們對慰藉的需求也加速了寵物飼養和伴侶動物健康的支出。寵物飼養量的激增以及人們對健康和福祉日益成長的關注擴大了目標市場，使新晉寵物飼主更願意投資高階獸醫服務，包括先進的再生醫學。此外，長期以來「寵物擬人化」的趨勢——這一趨勢本身就是重要的驅動力——在疫情期間得到了進一步強化。

在預測期內，「脂肪來源幹細胞（ADSCs）」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，脂肪幹細胞（ADSC）將佔據最大的市場佔有率，這主要得益於其儲量豐富、易於採集和再生能力強等優點。由於ADSC的採集只需進行微創手術，因此對於獸醫患者而言，它是一種更安全、更方便的選擇。除了在治療骨關節炎和異位性皮膚炎等疾病方面的有效性外，ADSC還因其採集部位併發症風險低於骨髓採集，而成為獸醫臨床實踐中首選的細胞來源。 ADSC療法在市場上的推廣及其在獸醫中的廣泛認可，正在鞏固其市場主導地位。

預計在預測期內，骨髓來源幹細胞（BMSC）細分市場將呈現最高的複合年成長率。

在預測期內，骨髓來源幹細胞（BMSC）領域預計將呈現最高的成長速度，這主要得益於採集技術的創新和治療應用的拓展。 BMSC歷來發揮至關重要的作用，如今，由於新技術提高了分離效率和療效，BMSC再次受到關注。在需要高分化潛能進行複雜組織再生（例如骨骼和軟骨修復）的情況下，BMSC尤其重要。隨著研究不斷揭示其獨特的潛力，以及採集方法的微創化，獸醫對BMSC的應用正在加速，使其成為成長最快的細胞來源領域。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其較高的寵物擁有率、在伴侶動物健康方面的大量支出以及完善的獸醫醫療保健基礎設施。該地區在幹細胞療法的商業化和專業應用方面也處於主導，這得益於許多大型生物技術公司的存在以及強大的臨床研究生態系統。該市場擁有穩固的財務基礎，美國寵物飼主越來越願意投資先進的醫療保健，預計到2025年，相關支出將超過1,570億美元。此外，隨著FDA對新型幹細胞產品的預期批准，北美的市場主導地位預計將進一步鞏固。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於寵物擁有量的快速成長、可支配收入的增加以及先進獸醫服務的普及。中國、澳洲、日本和韓國等國家引領著這一成長，不斷壯大的中產階級推動了高階寵物醫療保健的投資。該地區龐大且持續成長的伴侶動物數量，以及專科獸醫診所的興起，正在創造巨大的市場需求。隨著人們對再生醫學益處的認知不斷提高以及獸醫基礎設施的現代化，亞太地區預計將迎來最快的市場成長。

免費客製化服務：

所有購買此報告的客戶均可從以下免費自訂選項中選擇一項：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球獸醫幹細胞治療市場：依治療類型分類

  • 自體幹細胞治療
  • 異體幹細胞治療

第6章 全球獸用幹細胞治療市場：依細胞來源分類

  • 脂肪來源幹細胞
  • 骨髓來源幹細胞
  • 臍帶來源幹細胞
  • 周邊血液來源幹細胞
  • 其他細胞來源

第7章 全球獸用幹細胞治療市場：依動物類型分類

  • 狗
  • 貓
  • 馬
  • 家畜
  • 其他動物

第8章：全球獸醫幹細胞治療市場：依應用分類

  • 整形外科疾病
    • 骨關節炎
    • 關節疾病
    • 軟骨和骨骼疾病
  • 軟組織損傷
    • 肌腱損傷
    • 韌帶損傷
    • 肌肉損傷
  • 創傷治療和組織修復
  • 發炎性和免疫介導性疾病
  • 神經病變
  • 其他用途

第9章 全球獸醫幹細胞治療市場：依最終用戶分類

  • 獸醫醫院和診所
  • 獸醫學術和研究機構
  • 獸醫專科診所和再生醫學中心
  • 其他最終用戶

第10章：全球獸用幹細胞治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • VetStem Biopharma, Inc.
  • Boehringer Ingelheim International GmbH
  • Ardent Animal Health
  • Medrego GmbH
  • Gallant
  • Magellan
  • eQcell
  • VET-STEM, Inc.
  • Vetbiologics
  • Regeneus Ltd.
  • Cell Therapy Sciences
  • Dechra Pharmaceuticals Limited
  • Zoetis Inc.
  • Vetoquinol SA
  • Animal Cell Therapies, Inc.
  • VetMatrix
  • KeraVet Bio
  • Stemcell Holdings Inc.
Product Code: SMRC39449

According to Stratistics MRC, the Global Veterinary Stem Cell Therapy Market is accounted for $172.4 million in 2026 and is expected to reach $359.1 million by 2034 growing at a CAGR of 9.6% during the forecast period. Veterinary stem cell therapy is a rapidly advancing field of regenerative medicine that utilizes stem cells to repair damaged tissues, modulate inflammation, and manage chronic conditions in animals. These therapies are primarily applied in the treatment of osteoarthritis, orthopedic disorders, tendon and ligament injuries, and other degenerative conditions affecting companion and performance animals. The market encompasses various cell sources, including adipose-derived, bone marrow-derived, umbilical cord-derived, and peripheral blood-derived stem cells, with applications spanning a wide range of animal types.

Market Dynamics:

Driver:

Increasing pet humanization and demand for advanced veterinary care

The deepening emotional bond between pet owners and their companion animals is a primary driver for the veterinary stem cell therapy market. Pets are increasingly treated as family members, leading to a greater willingness among owners to invest in advanced, high-quality medical treatments to extend their pets' lives and improve their quality of life. This trend is reflected in rising pet spending globally, with U.S. pet expenditures projected to reach $157 billion in 2025. The growing demand for disease-modifying therapies that target the root cause of chronic conditions like osteoarthritis, rather than just managing symptoms, is propelling the adoption of stem cell-based regenerative treatments. As pet owners seek innovative, long-term solutions for their aging animals, the demand for stem cell therapies continues to rise.

Restraint:

High treatment costs and limited regulatory clarity

Despite significant growth potential, the veterinary stem cell therapy market faces considerable restraints, primarily due to high treatment costs and regulatory ambiguity. Stem cell therapies, which involve complex procedures for cell collection, processing, and administration, are expensive, limiting their accessibility to a broader pet owner base. The lack of uniform global regulatory standards for veterinary stem cell products creates uncertainty and can slow down the approval and commercialization of new therapies, particularly in regions with stringent oversight. This regulatory fragmentation can hinder market growth by limiting the number of available treatments and increasing the burden on manufacturers.

Opportunity:

Regulatory approvals and standardization of stem cell products

The anticipated regulatory approvals of standardized stem cell products present a significant opportunity for market expansion. For instance, Gallant's stem cell therapy for a painful feline condition is expected to receive U.S. FDA conditional approval, which would be a landmark event that could boost confidence among veterinarians and pet owners. This would validate the safety and efficacy of such treatments, encouraging wider clinical adoption and attracting more investment into the field. The development of scalable, off-the-shelf allogeneic therapies promises to streamline distribution and make regenerative treatments more accessible, filling critical gaps in care for chronic conditions.

Threat:

Competition from alternative therapies and evidence gaps

The veterinary stem cell therapy market faces threats from alternative treatments and ongoing debates about evidence depth. While stem cell therapy shows promise, it competes with other advanced modalities like platelet-rich plasma and conventional pharmaceuticals for treating similar conditions. The variable clinical evidence supporting stem cell efficacy across different applications and species can create skepticism among some veterinary practitioners. This, coupled with the high cost, may lead some veterinarians to prefer established, lower-cost alternatives for which long-term data is more robust. Overcoming this perception and building a stronger evidence base is crucial for market growth.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the veterinary stem cell therapy market. Initial disruptions included restricted access to veterinary clinics for non-essential procedures and disruptions in cell processing supply chains. However, the pandemic also accelerated pet ownership and spending on companion animal health, as people sought companionship during lockdowns. This surge in pet adoption and the heightened focus on health and wellness created a larger addressable market and increased the willingness of new pet owners to invest in premium veterinary services, including advanced regenerative therapies. The long-term trend of pet humanization, already a key driver, was reinforced during this period.

The Adipose-Derived Stem Cells segment is expected to be the largest during the forecast period

The Adipose-Derived Stem Cells (ADSCs) segment is expected to account for the largest market share during the forecast period, driven by their abundance, ease of extraction, and high regenerative potential. ADSCs are harvested through minimally invasive procedures, making them a safer and more accessible option for veterinary patients. Their efficacy in treating conditions like osteoarthritis and atopic dermatitis, coupled with a lower risk of donor-site morbidity compared to bone marrow extraction, has established them as the preferred cell source in veterinary practice. The established presence of ADSC-based therapies in the market and their widespread acceptance among veterinarians ensure their dominant position.

The Bone Marrow-Derived Stem Cells segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Bone Marrow-Derived Stem Cells (BMSCs) segment is predicted to witness the highest growth rate, fueled by innovations in extraction techniques and expanding therapeutic applications. Historically significant, BMSCs are now experiencing a resurgence as new technologies improve their isolation and efficacy. They are particularly valued in cases requiring higher differentiation capabilities for complex tissue regeneration, such as in bone and cartilage repair. As research continues to demonstrate their unique potential, and as extraction methods become less invasive, the adoption of BMSCs by veterinarians is accelerating, positioning it as the fastest-growing cell source segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, significant spending on companion animal health, and a well-established veterinary infrastructure. The region is a leader in the commercialization and specialist use of stem cell therapies, driven by the presence of key biotechnology firms and a strong clinical research ecosystem. The increasing willingness of U.S. pet owners to invest in advanced medical care, with spending projected to exceed $157 billion in 2025, provides a substantial financial base for the market. The anticipated FDA approval of new stem cell products is further expected to reinforce North America's dominant position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly increasing pet ownership, rising disposable incomes, and expanding access to advanced veterinary care. Countries like China, Australia, Japan, and South Korea are leading this expansion, with growing middle-class populations investing in premium pet healthcare. The region's large and growing companion animal population, coupled with an increasing number of specialty veterinary clinics, creates substantial demand. As awareness of regenerative medicine benefits grows and the veterinary infrastructure modernizes, the Asia-Pacific region is expected to deliver the fastest market growth.

Key players in the market

Some of the key players in Veterinary Stem Cell Therapy Market include VetStem Biopharma, Inc., Boehringer Ingelheim International GmbH, Ardent Animal Health, Medrego GmbH, Gallant, Magellan, eQcell, VET-STEM, Inc., Vetbiologics, Regeneus Ltd., Cell Therapy Sciences, Dechra Pharmaceuticals Limited, Zoetis Inc., Vetoquinol S.A., Animal Cell Therapies, Inc., VetMatrix, KeraVet Bio, and Stemcell Holdings Inc.

Key Developments:

In August 2026, Medrego launched dedicated regenerative medicine initiatives, introducing mesenchymal stem cells and exosome-based cellular applications tailored for elite falcons across avian practices in the Middle East.

In July 2026, eQcell secured an additional $4.6 million in venture backing to advance its late-stage clinical programs evaluating activated allogeneic umbilical cord blood-derived mesenchymal stromal cells (CB-MSCs) for equine joint disorders.

In January 2025, VetMatrix integrated advanced cellular bioprinting matrices into its regenerative veterinary research unit to assist academic clinics studying osteochondral defect regeneration.

Therapy Types Covered:

  • Autologous Stem Cell Therapy
  • Allogeneic Stem Cell Therapy

Cell Sources Covered:

  • Adipose-Derived Stem Cells
  • Bone Marrow-Derived Stem Cells
  • Umbilical Cord-Derived Stem Cells
  • Peripheral Blood-Derived Stem Cells
  • Other Cell Sources

Animal Types Covered:

  • Dogs
  • Cats
  • Horses
  • Livestock Animals
  • Other Animals

Applications Covered:

  • Orthopedic Disorders
  • Soft Tissue Injuries
  • Wound Healing and Tissue Repair
  • Inflammatory and Immune-Mediated Disorders
  • Neurological Disorders
  • Other Applications

End Users Covered:

  • Veterinary Hospitals and Clinics
  • Veterinary Academic and Research Institutes
  • Veterinary Specialty and Regenerative Medicine Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Veterinary Stem Cell Therapy Market, By Therapy Type

  • 5.1 Autologous Stem Cell Therapy
  • 5.2 Allogeneic Stem Cell Therapy

6 Global Veterinary Stem Cell Therapy Market, By Cell Source

  • 6.1 Adipose-Derived Stem Cells
  • 6.2 Bone Marrow-Derived Stem Cells
  • 6.3 Umbilical Cord-Derived Stem Cells
  • 6.4 Peripheral Blood-Derived Stem Cells
  • 6.5 Other Cell Sources

7 Global Veterinary Stem Cell Therapy Market, By Animal Type

  • 7.1 Dogs
  • 7.2 Cats
  • 7.3 Horses
  • 7.4 Livestock Animals
  • 7.5 Other Animals

8 Global Veterinary Stem Cell Therapy Market, By Application

  • 8.1 Orthopedic Disorders
    • 8.1.1 Osteoarthritis
    • 8.1.2 Joint Disorders
    • 8.1.3 Cartilage and Bone Disorders
  • 8.2 Soft Tissue Injuries
    • 8.2.1 Tendon Injuries
    • 8.2.2 Ligament Injuries
    • 8.2.3 Muscle Injuries
  • 8.3 Wound Healing and Tissue Repair
  • 8.4 Inflammatory and Immune-Mediated Disorders
  • 8.5 Neurological Disorders
  • 8.6 Other Applications

9 Global Veterinary Stem Cell Therapy Market, By End User

  • 9.1 Veterinary Hospitals and Clinics
  • 9.2 Veterinary Academic and Research Institutes
  • 9.3 Veterinary Specialty and Regenerative Medicine Centers
  • 9.4 Other End Users

10 Global Veterinary Stem Cell Therapy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 VetStem Biopharma, Inc.
  • 13.2 Boehringer Ingelheim International GmbH
  • 13.3 Ardent Animal Health
  • 13.4 Medrego GmbH
  • 13.5 Gallant
  • 13.6 Magellan
  • 13.7 eQcell
  • 13.8 VET-STEM, Inc.
  • 13.9 Vetbiologics
  • 13.10 Regeneus Ltd.
  • 13.11 Cell Therapy Sciences
  • 13.12 Dechra Pharmaceuticals Limited
  • 13.13 Zoetis Inc.
  • 13.14 Vetoquinol S.A.
  • 13.15 Animal Cell Therapies, Inc.
  • 13.16 VetMatrix
  • 13.17 KeraVet Bio
  • 13.18 Stemcell Holdings Inc.

List of Tables

  • Table 1 Global Veterinary Stem Cell Therapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Veterinary Stem Cell Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Veterinary Stem Cell Therapy Market Outlook, By Autologous Stem Cell Therapy (2023-2034) ($MN)
  • Table 4 Global Veterinary Stem Cell Therapy Market Outlook, By Allogeneic Stem Cell Therapy (2023-2034) ($MN)
  • Table 5 Global Veterinary Stem Cell Therapy Market Outlook, By Cell Source (2023-2034) ($MN)
  • Table 6 Global Veterinary Stem Cell Therapy Market Outlook, By Adipose-Derived Stem Cells (2023-2034) ($MN)
  • Table 7 Global Veterinary Stem Cell Therapy Market Outlook, By Bone Marrow-Derived Stem Cells (2023-2034) ($MN)
  • Table 8 Global Veterinary Stem Cell Therapy Market Outlook, By Umbilical Cord-Derived Stem Cells (2023-2034) ($MN)
  • Table 9 Global Veterinary Stem Cell Therapy Market Outlook, By Peripheral Blood-Derived Stem Cells (2023-2034) ($MN)
  • Table 10 Global Veterinary Stem Cell Therapy Market Outlook, By Other Cell Sources (2023-2034) ($MN)
  • Table 11 Global Veterinary Stem Cell Therapy Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 12 Global Veterinary Stem Cell Therapy Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 13 Global Veterinary Stem Cell Therapy Market Outlook, By Cats (2023-2034) ($MN)
  • Table 14 Global Veterinary Stem Cell Therapy Market Outlook, By Horses (2023-2034) ($MN)
  • Table 15 Global Veterinary Stem Cell Therapy Market Outlook, By Livestock Animals (2023-2034) ($MN)
  • Table 16 Global Veterinary Stem Cell Therapy Market Outlook, By Other Animals (2023-2034) ($MN)
  • Table 17 Global Veterinary Stem Cell Therapy Market Outlook, By Application (2023-2034) ($MN)
  • Table 18 Global Veterinary Stem Cell Therapy Market Outlook, By Orthopedic Disorders (2023-2034) ($MN)
  • Table 19 Global Veterinary Stem Cell Therapy Market Outlook, By Osteoarthritis (2023-2034) ($MN)
  • Table 20 Global Veterinary Stem Cell Therapy Market Outlook, By Joint Disorders (2023-2034) ($MN)
  • Table 21 Global Veterinary Stem Cell Therapy Market Outlook, By Cartilage and Bone Disorders (2023-2034) ($MN)
  • Table 22 Global Veterinary Stem Cell Therapy Market Outlook, By Soft Tissue Injuries (2023-2034) ($MN)
  • Table 23 Global Veterinary Stem Cell Therapy Market Outlook, By Tendon Injuries (2023-2034) ($MN)
  • Table 24 Global Veterinary Stem Cell Therapy Market Outlook, By Ligament Injuries (2023-2034) ($MN)
  • Table 25 Global Veterinary Stem Cell Therapy Market Outlook, By Muscle Injuries (2023-2034) ($MN)
  • Table 26 Global Veterinary Stem Cell Therapy Market Outlook, By Wound Healing and Tissue Repair (2023-2034) ($MN)
  • Table 27 Global Veterinary Stem Cell Therapy Market Outlook, By Inflammatory and Immune-Mediated Disorders (2023-2034) ($MN)
  • Table 28 Global Veterinary Stem Cell Therapy Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 29 Global Veterinary Stem Cell Therapy Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 30 Global Veterinary Stem Cell Therapy Market Outlook, By End User (2023-2034) ($MN)
  • Table 31 Global Veterinary Stem Cell Therapy Market Outlook, By Veterinary Hospitals and Clinics (2023-2034) ($MN)
  • Table 32 Global Veterinary Stem Cell Therapy Market Outlook, By Veterinary Academic and Research Institutes (2023-2034) ($MN)
  • Table 33 Global Veterinary Stem Cell Therapy Market Outlook, By Veterinary Specialty and Regenerative Medicine Centers (2023-2034) ($MN)
  • Table 34 Global Veterinary Stem Cell Therapy Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.